 | |
| Clinical data | |
|---|---|
| Other names | (S)-(+)-2β-Carbomethoxy-3α-(bis(4-fluorophenyl)methoxy)tropane |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H25F2NO3 |
| Molar mass | 401.454 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Difluoropine (O-620) is astimulant drug synthesised fromtropinone, which acts as a potent and selectivedopamine reuptake inhibitor. Difluoropine is unique among the tropane-derived dopamine reuptake inhibitors in that the activestereoisomer is the (S) enantiomer rather than the (R) enantiomer, the opposite way round compared to naturalcocaine.[1] It is structurally related tobenztropine and has similaranticholinergic andantihistamine effects in addition to its dopamine reuptake inhibitory action.[2]
Difluoropine has some stimulant effects in animals, although it is significantly less powerful than many of the potentphenyltropane derived stimulant drugs such asWIN 35,428 andRTI-55.[3] It showed promising effects in alleviating the symptoms ofParkinson's disease in an animal model of the disorder.[4]
It is not explicitly illegal anywhere in the world as of 2008[update], but might be considered to be acontrolled substance analogue of cocaine on the grounds of its related chemical structure, in some jurisdictions such as the United States, Canada, Australia and New Zealand.
